Paul this whole article is ridiculing Pacific Biosciences.
“We came in and we took a look at the data, and we asked what the strategy was” said Michael Caterpiller, CEO. “The board thought that their really crappy error rate gave them a unique niche in the market, and that niche needed to be defended. Some in the company actually thought we should increase the error rate, and blow everyone else out of the market in terms of poor quality data” he continued."